Curriculum vitae
`
`
`
`Jayesh Mehta
`
`
`Current Appointment Professor of Medicine
`Northwestern University Feinberg School of Medicine
`The Robert H Lurie Comprehensive Cancer Center of Northwestern University
`(December 2000 onwards)
`
`Director, Northwestern Hematopoietic Stem Cell Transplant Program
`(December 2000 onwards)
`
`Deputy Director, Northwestern University Comprehensive Transplant Center
`(June 2010 onwards)
`
`
`
`Contact information
`
`
`
`
`Previous
`Appointments
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`676 N Saint Clair Street, Suite 850
`Chicago, IL 60611-2927
`Phone: 312-695-6180
`FAX: 312-695-6189
`j-mehta@northwestern.edu
`
`Professor of Medicine
`Clinical Director, Division of Transplantation Medicine
`Director, Myeloma and Lymphoma Program
`South Carolina Cancer Center and Palmetto Richland Memorial Hospital
`University of South Carolina, Columbia, South Carolina
`(July 1999 to October 2000)
`
`Associate Professor of Medicine
`Chief, Section of Allogeneic Stem Cell Transplantation (1998-99)
`Myeloma and Transplantation Research Center
`University of Arkansas for Medical Sciences, Little Rock, Arkansas
`(July 1996 to June 1999)
`
`Lecturer in Hematology
`Seth GS Medical College and King Edward VII Memorial Hospital, Bombay, India
`(March to October 1990)
`
`
`
`Personal
`
`
`
`
`
`
`
`Educational
`Qualifications
`
`
`
`Medical studies
`
`
`
`
`
`
`
`
`
`
`
`Date of Birth: 20 August 1964
`Spouse: Seema Singhal MD
`Citizenship: US
`
`MBBS, Bombay University, 1985
`MD (Internal Medicine), Bombay University, 1990
`
`Undergraduate, Seth GS Medical College, Bombay (1981-1985)
`Rotating internship, KEM Hospital, Bombay (1986)
`Postgraduate, Seth GS Medical College & KEM Hospital (1987-1989)
`
`Page 1 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`House Officer, Internal Medicine, 6 months
`House Officer, Internal Medicine/Neurology, 6 months
`House Officer, Internal Medicine/Cardiology, 6 months
`Registrar, Internal Medicine/Gastroenterology, 6 months
`Registrar, Internal Medicine/Hematology, 1 year
`
`Department of Bone Marrow Transplantation and Cancer Immunobiology
`Hadassah University Hospital, Jerusalem, Israel
`(March 1991 to March 1992)
`
`Senior Registrar and Bone Marrow Transplant Coordinator
`Leukaemia and Myeloma Units, Department of Medical Oncology
`Royal Marsden Hospital, Surrey, UK
`(April 1992 to July 1996)
`
`Internal medicine (ABIM): Certified through 2015
`Hematology (ABIM Subspecialty): Certified through 2020
`Oncology (ABIM Subspecialty): Eligible
`
`ECFMG/USMLE: Certified (Steps I-III)
`Illinois Department of Professional Regulation (Active)
`Maharashtra Medical Council (Medical Council of India) (Active)
`
`Inactive: Arkansas State Medical Board, South Carolina Board of Medical
`Examiners, General Medical Council (London, UK), Israeli Medical Council
`
`
`Co-Editor, Bone Marrow Transplantation, June 1998 to December 2008
`Deputy Editor, Bone Marrow Transplantation, January 2009 to March 2014
`Editorial Board, Biology of Blood and Marrow Transplantation (2007 onwards)
`Editorial Board, Blood (2009-2013)
`Editorial Board, Clinical Leukemia (2006-2009)
`
`
`
`Referee:
`
`American Journal of Hematology, American Journal of Medicine, Annals of
`Oncology, Archives of Internal Medicine, Blood, Bone Marrow Transplantation,
`British Journal of Haematology, Clinical Cancer Research European Journal of
`Cancer, Clinical Infectious Diseases, Clinical Leukemia, Haematologica, The
`Hematology Journal, JAMA, Journal of Clinical Oncology, Journal of
`Hematotherapy, Leukemia, Leukemia and Lymphoma, Mayo Clinic Proceedings,
`Nature Reviews Cancer
`
`
`American Society of Blood and Marrow Transplantation
`American Society of Hematology
`
`Multiple myeloma
`Hematopoietic stem cell transplantation
`Use of hematopoietic stem cells for experimental and clinical tissue repair
`Opportunistic infections in immunocompromised patients
`
`Page 2 of 69
`
`
`
`
`
`
`
`
`
`
`
`Residency
`(1987-1989)
`
`
`
`
`Fellowship
`(1991-1996)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Board certifications
`
`
`
`
`
`
`
`
`
`Licensure
`
`
`
`
`
`Journals/
`Editorial Boards
`
`
`
`
`
`
`
`
`
`
`
`
`Professional socities
`
`
`
`
`
`
`Research interests
`
`
`
`
`
`
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`Major grants (PI/Co-PI) $50,000 – State of Illinois – Excellence in Academic Medicine – 2001-02
`
`
`
`“Protocol development in hematopoietic stem cell transplantation”
`
`$1.5 million – Northwestern Memorial Foundation – 2004-06
`“Establishment of a cGMP cell processing facility and advanced cell therapy”
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`$2.873 million – State of Illinois – Excellence in Acdemic Medicine – 2004-08
`“Establishment of a cGMP cell processing facility”
`
`$0.5 million – Illinois Regenerative Medicine Institute – 2007-09
`Jointly with University of Illinois, Urbana-Champaign (total award $1 million)
`“Evaluation of a new high-speed cell sorter as an enabling technology for cell
`therapy”
`
`$250,000 – Chicago Biomedical Consortium – 2007-10
`Jointly with University of Chicago and University of Illinois at Chicago (total award
`$3 million)
`“Tooth regeneration”
`
`
`
`
`
`
`
`
`
`
`
`Patents
`
`Mehta J, Singhal S, Beohar N, Davidson C, Bonow R. G-CSF therapy as an adjunct to reperfusion therapy
`in the treatment of acute myocardial infarction. US Patent 7,220,407 (Issued 22 May 2007).
`
`Zhao LR, Kessler J, Singhal S, Mehta J. Use of SCF and G-CSF in the treatment of cerebral ischemia and
`neurological disorders. US Patent 8,524,655 (Issued 3 September 2013).
`
`Zhao LR, Kessler J, Singhal S, Mehta J. Use of SCF and G-CSF in the treatment of cerebral ischemia and
`neurological disorders. European Patent EP 1817047 B1 (Issued 8 February 2012).
`
`Zhao LR, Mehta J, Singhal S, Kessler J. Use of SCF and G-CSF in the treatment of cerebral ischemia and
`neurological disorders. Australian Patent 2005306894 (Issued 12 March 2012).
`
`Page 3 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`Bibliography
`
`
`
`Book
`
`1. Mehta J, Singhal S, eds. Myeloma. London, Martin Dunitz, 2002 (ISBN 1-901865-50-9).
`
`
`
`Blood and Marrow Transplantation
`
`
`2. Mehta J, Nagler A, Schechter D, Rein AJJT, Slavin S. Acute fatal cardiomyopathy associated with "non-
`cardiotoxic" chemotherapy for autologous bone marrow transplantation. Am J Hematol 1992; 40:242.
`
`
`3. Or R, Mehta J, Nagler A, Craciun I. Neutropenic enterocolitis associated with autologous bone marrow
`transplantation. Bone Marrow Transplant 1992; 9:383-385.
`
`
`4. Mehta J, Singhal S, Or R. Cyclophosphamide-induced cardiomyopathy during bone marrow
`transplantation for severe aplastic anemia. J Assoc Physicians India 1994; 42:159-160.
`
`
`5. Mehta J, Nagler A, Slavin S. Marrow transplantation for multiple myeloma. N Engl J Med 1992;
`326:1087-1088.
`
`
`6. Mehta J, Nagler A, Or R, Kapelushnik J, Slavin S. Neutropenic enterocolitis and intestinal perforation
`associated with carboplatin-containing conditioning regimen for autologous bone marrow
`transplantation. Acta Oncol 1992; 31:591.
`
`
`7. Or R, Mehta J, Naparstek E, Okon E, Cividalli G, Slavin S. Successful T cell-depleted allogeneic bone
`marrow transplantation in a child with recurrent multiple extramedullary plasmacytomas. Bone Marrow
`Transplant 1992; 10:381-382.
`
`
`8. Mehta J, Nagler A, Ackerstein A, Kapelushnik J, Or R. Cutaneous hypersensitivity to co-trimoxazole
`after autologous bone marrow transplantation and immunotherapy with interferon alpha-2a and
`interleukin-2. J Assoc Physicians India 1993; 41:235-236.
`
`
`9. Mehta J. Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma
`1993; 10:427-432.
`
`
`10. Tiley C, Powles R, Treleaven J, Catovsky D, Milan S, Teo CP, Catalano J, Mehta J, Shields M, Gupta P,
`Richards S, Millar J, Gorman C. Feasibility and efficacy of maintenance chemotherapy following
`autologous bone marrow transplantation for first remission acute lymphoblastic leukaemia. Bone Marrow
`Transplant 1993; 12:449-455.
`
`
`11. Powles RL, Mehta J. Systemic fungal infections: Major problems in cancer patients. Indian J Cancer
`1994; 31:180-184.
`
`
`12. Treleaven JG, Mehta J. Bone marrow and peripheral stem cell harvesting. J Hematother 1992; 1:215-
`223.
`
`
`13. Mehta J, Powles RL, Shepherd V, Dainton M, Treleaven J. Transplantation of autologous peripheral
`blood stem cells mobilized using GM-CSF for acute leukemia with myelofibrosis. Leuk Lymphoma
`1993; 11:157-158.
`
`
`14. Or R, Mehta J, Kapelushnik J, Aker M, Naparstek E, Nagler A, Cividalli G, Slavin S. Total lymphoid
`irradiation, anti-lymphocyte globulin and CAMPATH 1-G for immunosuppression prior to bone marrow
`
`Page 4 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`transplantation for severe aplastic anemia after repeated graft rejection. Bone Marrow Transplant
`1994; 13:97-99.
`
`
`15. Mehta J, Powles R, Treleaven J, Shields M, Agrawal S, Rege K, Mitchell P, Allard S. Cimetidine-
`induced myelosuppression after bone marrow transplantation. Leuk Lymphoma 1994; 13:179-181.
`
`
`16. Mehta J, Powles RL, Mitchell P, Rege K, De Lord C, Treleaven J. Graft failure after bone marrow
`transplantation from unrelated donors using busulphan and cyclophosphamide for conditioning. Bone
`Marrow Transplant 1994; 13:583-587.
`
`
`17. Mitchell P, Powles R, Treleaven J, Rege K, Mehta J, Jameson B. Topical phenoxyethanolamine for
`Pseudomonas infections in neutropenic patients. J Hosp Infection 1993; 25:53-56.
`
`
`18. Kapelushnik J, Nagler A, Or R, Naparstek E, Cividalli G, Aker M, Mehta J, Mumcuoglu M, Slavin S.
`Autologous bone marrow transplantation for stage IV neuroblastoma: the role of soybean agglutinin
`purging. Transplant Proc 1993; 25:2375-2376.
`
`
`19. Mehta J, Powles R, Horton C, Milan S, Treleaven J, Tait D, Catovsky D. Bone marrow transplantation
`for primary refractory acute leukaemia. Bone Marrow Transplant 1994; 14:415-418.
`
`
`20. Perry A, Mehta J, Iveson T, Treleaven J, Powles R. Guillain-Barre syndrome after bone marrow
`transplantation. Bone Marrow Transplant 1994; 14:165-167.
`
`
`21. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. II: Antimicrobial therapy
`and prophylaxis. Postgrad Doctor Middle East 1994; 17:392-399.
`
`
`22. Rege K, Mehta J, Treleaven J, Jameson B, Meller ST, Mitchell P, Milan S, Powles RL. Fatal
`pneumococcal infections following allogeneic bone marrow transplantation. Bone Marrow Transplant
`1994; 14:903-906.
`
`
`23. Singhal S, Mehta J, Powles R, Treleaven J, Horton C, Carrington D, Tryhorn Y, Jameson B. Three
`weeks of ganciclovir for cytomegaloviraemia after allogeneic bone marrow transplantation. Bone
`Marrow Transplant 1995; 15:777-781.
`
`
`24. Zomas A, Mehta J, Powles R, Treleaven J, Iveson T, Singhal S, Jameson B, Paul B, Brincat S,
`Catovsky D. Unusual infections following allogeneic bone marrow transplantation for chronic
`lymphocytic leukemia. Bone Marrow Transplant 1994; 14:799-803.
`
`
`25. Mehta J, Singhal S, Powles R. Approach to the febrile neutropenic patient. I: General principles of
`management. Postgrad Doctor Middle East 1994; 17:327-333.
`
`
`26. Mehta J. Interferon alfa-2a for chronic myeloid leukemia. N Engl J Med 1994; 331:401-402.
`
`27. Singhal S, Mehta J, Powles R. Prevention of cytomegalovirus disease by a short course of
`preemptive ganciclovir or foscarnet. Blood 1994; 84:2055.
`
`
`28. Powles R, Mehta J, Singhal S, Horton C, Tait D, Milan S, Pollard C, Lumley H, Matthey F, Shirley J,
`Williams H, Samaratunga I, Lakhani A, Millar J, Treleaven J. Autologous bone marrow or peripheral
`blood stem cell transplantation followed by maintenance chemotherapy for adult acute lymphoblastic
`leukemia in first remission: 50 cases from a single center. Bone Marrow Transplant 1995; 16:241-247.
`
`
`29.
`
`Lampe H, Dearnaley DP, Price A, Mehta J, Powles R, Nicholls J, Horwich A. High-dose carboplatin
`and etoposide for salvage therapy of germ cell tumours. Eur J Cancer 1995; 31A:717-723.
`
`
`30. Chang J, Powles R, Mehta J, Paton N, Treleaven J, Jameson B. Listeriosis in bone marrow transplant
`recipients: incidence, clinical features, and treatment. Clin Infect Dis 1995; 21:1289-1290.
`
`Page 5 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`
`31. Mehta J, Powles R, Horton C, Milan S, Singhal S, Treleaven J. The relationship between donor-
`recipient blood group incompatibility and serum bilirubin after allogeneic bone marrow transplantation
`from HLA-identical siblings. Bone Marrow Transplant 1995; 15:853-858.
`
`
`32. Mehta J, Powles R, Singhal S, Treleaven J. Peripheral blood stem cell transplantation may result in
`increased relapse of acute myeloid leukaemia due to reinfusion of a higher number of malignant cells.
`Bone Marrow Transplant 1995; 15:652-653.
`
`
`33. Singhal S, Mehta J, Rattenbury H, Treleaven J, Powles R. Oral pilocarpine hydrochloride for the
`treatment of refractory xerostomia associated with chronic graft-versus-host disease. Blood 1995;
`85:1147-1148.
`
`
`34. Singhal S, Powles R, Milan S, Raje N, Viner C, Treleaven J, Cunningham D, Mehta J. Clearance of
`paraprotein after autografting for multiple myeloma. Bone Marrow Transplant 1995; 16:537-540.
`
`
`35. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S, Meller S, Pinkerton CR, Treleaven J.
`Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of
`modifiable prognostic factors. Bone Marrow Transplant 1995; 16:499-506.
`
`
`36. Mehta J, Powles R, Cabral S, Shepherd V, Singhal S, Morilla R, Treleaven J. Comparison of Cobe
`Spectra and Haemonetics MCS-3P cell separators for peripheral blood stem cell harvesting. Bone
`Marrow Transplant 1995; 16:707-709.
`
`
`37. Mehta J, Powles R, Singhal S, Tait D, Swansbury J, Treleaven J. Cytokine-mediated immunotherapy
`with or without donor leukocytes for poor-risk acute myeloid leukemia relapsing after allogeneic bone
`marrow transplantation. Bone Marrow Transplant 1995; 16:133-137.
`
`
`38. Dunlop L, Powles R, Singhal S, Treleaven J, Swansbury GJ, Meller S, Pinkerton CR, Horton C, Mehta
`J. Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia.
`Bone Marrow Transplant 1996; 17:365-369.
`
`
`39. Singhal S, Powles R, Treleaven J, Lumley H, Pollard C, Mehta J. Allogeneic bone marrow
`transplantation for primary myelofibrosis. Bone Marrow Transplant 1995; 16:743-746.
`
`
`40. Chang J, Powles R, Singhal S, Jameson B, Treleaven J, Mehta J. Foscarnet therapy for
`cytomegalovirus infection after allogeneic bone marrow transplantation. Clin Infect Dis 1996; 22:583-
`584.
`
`
`41. Mehta J, Mijovic A, Powles R, Pagliuca A, Singhal S, Czepulkowski B, Swansbury GJ, Treleaven J,
`Mufti GJ. Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia.
`Bone Marrow Transplant 1996; 17:25-29.
`
`
`42. Mehta J, Powles R, Singhal S, Iveson T, Treleaven J, Catovsky D. Clinical and hematologic response
`of chronic lymphocytic and prolymphocytic leukemia persisting after allogeneic bone marrow
`transplantation with the onset of acute graft-versus-host disease: possible role of graft-versus-
`leukemia. Bone Marrow Transplant 1996; 17:371-375.
`
`
`43. Mehta J, Powles R, Singhal S, Horton C, Treleaven J. Outcome of autologous rescue after failed
`engraftment of allogeneic marrow. Bone Marrow Transplant 1996; 17:213-217.
`
`
`44. Singhal S, Vourka-Karussis U, Mehta J, Slavin S, Weiss L. Failure of cyclosporine to induce graft-vs-
`host disease or graft-vs-leukemia after syngeneic bone marrow transplantation in mice. Leuk Res
`1996; 20:941-946.
`
`
`
`Page 6 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`45. Stewart A, Powles R, Hewetson M, Antrum J, Richardson C, Mehta J. Costs of antifungal prophylaxis
`after bone marrow transplantation: A model comparing oral fluconazole, liposomal amphotericin and
`oral polyenes as prophylaxis against oropharyngeal infections. PharmacoEconomics 1995; 8:350-
`361.
`
`
`46. Glynne P, Powles R, Steele J, Singhal S, Treleaven J, Tait D, Mehta J. Renal dysfunction following
`autologous bone marrow transplantation in adult patients with acute leukemia. Acta Oncol 1996;
`35:709-712.
`
`
`47. Powles R, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C,
`Treleaven J. Maintenance therapy for remission in myeloma with Intron A following high-dose
`melphalan and either an autologous bone marrow transplantation or peripheral blood stem cell
`rescue. Stem Cells 1995; 13 (Suppl 2):114-117.
`
`
`48. Mehta J, Powles R, Singhal S, Matthey F, Hamblin M, Middleton G, Prendiville J, Glynne P, Zomas A,
`Treleaven J, Catovsky D. T-cell depleted allogeneic bone marrow transplantation from a partially
`HLA-mismatched unrelated donor for progressive chronic lymphocytic leukemia and fludarabine-
`induced bone marrow failure. Bone Marrow Transplant 1996; 17:881-883.
`
`
`49. Hiorns L, Swansbury GJ, Mehta J, Min T, Treleaven J, Powles R, Catovsky D. Additional
`chromosomal abnormalities confer a worse prognosis in acute promyelocytic leukemia. Br J Haematol
`1997; 96:314-321.
`
`
`50. Hjiyannakis P, Mehta J, Milan S, Powles R, Hinson J, Tait D. Melphalan, single-fraction total-body
`irradiation and allogeneic bone marrow transplantation for acute leukaemia: review of transplant-
`related mortality. Leuk Lymphoma 1997; 25:565-572.
`
`
`51. Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T, Viner C, Milan S, Treleaven J,
`Cunningham D. Comparison of interferon tolerance after autologous bone marrow or peripheral blood
`stem cell transplants for myeloma patients who have responded to induction therapy.Leuk Lymphoma
`1996; 21:421-427.
`
`
`52. Mehta J, Powles R, Singhal S, Swansbury GJ, Millar B, Shepherd V, Bell J, Min T, Cabral S,
`Treleaven J. High-dose hydroxyurea and G-CSF to collect Philadelphia-negative cells in chronic
`myeloid leukemia. Leuk Lymphoma 1996; 23:107-111.
`
`
`53. Singhal S, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Mehta J. Central nervous
`system relapse after bone marrow transplantation for acute leukemia in first remission. Bone Marrow
`Transplant 1996; 17:637-641.
`
`
`54. Mehta J, Powles R, Singhal S, Horton C, Hamblin M, Zomas A, Saso R, Treleaven J. Transfusion
`requirements after bone marrow transplantation from HLA-identical siblings: effects of donor-recipient
`ABO incompatibility. Bone Marrow Transplant 1996; 18:151-156.
`
`
`55. Mehta J, Powles R, Singhal S, Horton C, Tait D, Treleaven J. Melphalan-total body irradiation and
`autologous bone marrow transplantation for adult acute leukemia beyond first remission. Bone
`Marrow Transplant 1996; 18:119-123.
`
`
`56. Mehta J. The first clinical use of donor leukocyte infusions for the treatment of leukemia relapsing
`after allogeneic bone marrow transplantation. Blood 1996; 87:4010.
`
`
`57. Singhal S, Powles R, Treleaven J, Rattenbury H, Mehta J. Pilocarpine hydrochloride for symptomatic
`relief of xerostomia due to chronic graft-versus-host disease or total-body irradiation after bone-
`marrow transplantation for hematologic malignancies. Leuk Lymphoma 1997; 24:539-543.
`
`
`
`Page 7 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`58. Mehta J, Powles R, Treleaven J, Horton C, Shepherd V, Hale G, Waldmann H, Singhal S. Autologous
`transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia:
`long-term follow-up. Leuk Lymphoma 1997; 25:479-486.
`
`
`59. Duncan N, Hewetson M, Powles R, Raje N, Mehta J. An economic evaluation of peripheral blood
`stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple
`myeloma. Bone Marrow Transplant 1996; 18:1175-1178.
`
`
`60. Kapelushnik J, Engelhard D, Mehta J, Or R, Brandstetter Y, Picard E, Cividalli G, Nagler A.
`Sequential respiratory syncytial virus and cytomegalovirus pneumonia following bone marrow
`transplantation. J Med Virol 1995; 46:169-171.
`
`
`61. Millar BC, Millar JL, Bell JBG, Raje N, Milan S, Mehta J, Singhal S, Middleton GW, Shepherd V,
`Catovsky D, Powles RL. Role of CD34+ cells in engraftment after high-dose melphalan in multiple
`myeloma patients given peripheral blood stem cell rescue. Bone Marrow Transplant 1996; 18:871-
`878.
`
`
`62. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Factors affecting engraftment and
`hematopoietic recovery after unpurged autografting in acute leukemia. Bone Marrow Transplant 1996;
`18:319-324.
`
`
`63. Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Long-term safety of GM-CSF (molgramostim)
`administration after allogeneic bone marrow transplantation for hematologic malignancies: five-year
`follow-up of a double-blind randomized placebo-controlled study. Leuk Lymphoma 1997; 24:301-307.
`
`
`64. Mehta J, Powles R, Treleaven J, Horton C, Tait D, Meller S, Pinkerton CR, Middleton G, Eisen T,
`Singhal S. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for
`acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and
`cyclosporine. Bone Marrow Transplant 1996; 18:741-746.
`
`
`65. Marcoullis G, Mehta J, Treleaven J. Autologous bone marrow and peripheral blood stem cell
`transplantation in haematological malignancies - current status. Med Oncol 1995; 12:209-218.
`
`
`66. Singhal S, Powles R, Treleaven J, Horton C, Pinkerton CR, Meller S, Mehta J. Cytomegaloviremia
`after autografting for leukemia: clinical significance and lack of effect on engraftment. Leukemia 1997;
`11:835-838.
`
`
`67. Singhal S, Powles R, Treleaven J, Horton C, Mehta J. Melphalan alone prior to allogeneic bone
`marrow transplantation from HLA-identical sibling donors for hematologic malignancies:
`alloengraftment with potential preservation of fertility. Bone Marrow Transplant 1996; 18:1049-1055.
`
`
`68. Mehta J, Powles R, Singhal S, Horton C, Middleton G, Eisen T, Meller S, Pinkerton CR, Treleaven J.
`Early identification of patients at risk of death due to infections, hemorrhage, or graft failure after
`allogeneic bone marrow transplantation on the basis of the leukocyte counts. Bone Marrow
`Transplant 1997; 19:349-355.
`
`
`69. Mehta J, Powles R, Treleaven J, Millar B, Proctor H, Cabral S, Shepherd V, Singhal S. A prospective,
`concurrent comparison of the Cobe Spectra and Haemonetics MCS-3P cell separators for
`leukapheresis after high-dose filgrastim in patients with haematologic malignancies. J Clin Apheresis
`1997; 12:63-67.
`
`
`70. Mehta J, Powles R, Treleaven J, Horton C, Meller S, Pinkerton CR, Singhal S. Outcome of acute
`leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive
`immunotherapy. Bone Marrow Transplant 1997; 19:709-719.
`
`
`
`Page 8 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`71. Singhal S, Powles R, Treleaven J, Mehta J. Sensitivity of secondary acute myeloid leukemia relapsing
`after allogeneic bone marrow transplantation to immunotherapy with interferon-(cid:68)2b. Bone Marrow
`Transplant 1997; 19:1151-1153.
`
`
`72. Mehta J, Powles R, Singhal S, Riley U, Treleaven J, Catovsky D. Antimicrobial prophylaxis to prevent
`opportunistic infections in patients with chronic lymphocytic leukemia after allogeneic blood or marrow
`transplantation. Leuk Lymphoma 1997; 26:83-88.
`
`
`73. Raje N, Powles R, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven
`J, Cunningham D, Gore M. A comparison of vincristine and doxorubicin infusional chemotherapy with
`methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction
`treatment followed by autografting in previously untreated myeloma. Br J Haematol 1997; 97:153-160.
`
`
`74. Saso R, Zomas A, Hamblin M, Dunlop L, Swansbury GJ, Min T, Singhal S, Powles R, Treleaven J,
`Mehta J. Sequential development of myelodysplasia and acute myeloid leukemia but with no
`karyotypic evolution after autografting in a patient with Philadelphia positive acute lymphoblastic
`leukemia. Leuk Lymphoma 1997; 26:625-628.
`
`
`75. Mehta J, Kelsey SM, Chu P, Powles R, Hazel D, Reilly U, Evans C, Newland A, Treleaven J, Singhal
`S. Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections
`in immunocompromised patients with hematologic malignancies. Bone Marrow Transplant 1997;
`20:39-43.
`
`
`76. Mehta J, Tricot G, Jagannath S, Desikan KR, Siegel D, Singhal S, Munshi N, Vesole D, Mattox S,
`Bracy D, Barlogie B. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and
`autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow
`Transplant 1997; 20:113-116.
`
`
`77. Mehta J, Chu P, Powles R, Kelsey S. Amphotericin B lipid complex for the treatment of presumed or
`confirmed fungal infections in immunocompromised patients with hematologic malignancies. Drugs
`Today 1996; 32 (Suppl G):27-32.
`
`
`78. Mehta J, Powles R, Treleaven J, Kulkarni S, Singhal S. Induction of graft-versus-host disease as
`immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32
`adult patients. Bone Marrow Transplant 1997; 20:129-135.
`
`
`79. Mehta J, Powles R, Horton C, Treleaven J, Singhal S. Leukocyte recovery and early treatment-related
`mortality after bone marrow transplantation. Blood 1997; 89:4237-4238.
`
`
`80. Singhal S, Mehta J, Barlogie B. Advances in the treatment of multiple myeloma. Curr Opin Hematol
`1997; 4:291-297.
`
`
`81. Mehta J, Tricot G, Jagannath S, Ayers D, Singhal S, Siegel D, Desikan K, Munshi N, Fassas A,
`Mattox S, Bracy D, Vesole D, Crowley J, Barlogie B. Salvage autologous or allogeneic transplantation
`for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant
`1998; 21:887-892.
`
`
`82. Mehta J, Powles R, Treleaven J, Kulkarni S, Horton C, Singhal S. Number of nucleated cells infused
`during allogeneic and autologous bone marrow transplantation: an important modifiable factor
`influencing outcome. Blood 1997; 90:3808-3810.
`
`
`83. Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, Kulkarni S, Eisen T, Mehta J,
`Singhal S, Treleaven J. Comparison of marrow vs blood-derived stem cells for autografting in
`previously untreated multiple myeloma. Br J Cancer 1997; 75:1684-1689.
`
`
`
`Page 9 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`84. Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M,
`Cunningham D, Treleaven J. Outcome assessment of a population-based group of 195 unselected
`myeloma patients under 70 years of age offered intensive treatment. Bone Marrow Transplant 1997;
`20:435-443.
`
`
`85. Powles R, Singhal S, Treleaven J, Kulkarni S, Horton C, Mehta J. Identification of patients who may
`benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid
`leukemia on the basis of lymphocyte recovery after transplantation. Blood 1998; 91:3481-3486.
`
`
`86. Zomas A, Stefanoudaki K, Fisfis M, Papadaki T, Mehta J. Graft-versus-myeloma after donor leukocyte
`infusion: maintenance of marrow remission but extramedullary relapse with plasmacytomas. Bone
`Marrow Transplant 1998; 21:1163-1165.
`
`
`87. Zomas A, Saso R, Powles R, Mackay H, Singhal S, Treleaven J, Mehta J. Red cell fragmentation
`(schistocytosis) after bone marrow transplantation. Bone Marrow Transplant 1998; 22:777-780.
`
`
`88. Singhal S, Powles R, Kulkarni S, Treleaven J, Saso R, Mehta J. Long-term follow-up of relapsed
`acute leukemia treated with immunotherapy after allogeneic transplantation: the inseparability of graft-
`versus-host disease and graft-versus-leukemia, and the problem of extramedullary relapse. Leuk
`Lymphoma 1999; 32:505-512.
`
`
`89. Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow
`Transplant 1999; 23:637-646.
`
`
`90. Mehta J, Singhal S. Graft-versus-myeloma. Bone Marrow Transplant 1998; 22:835-843.
`
`91. Singhal S, Powles R, Kulkarni S, Treleaven J, Sirohi B, Millar B, Shepherd V, Saso R, Rowland A,
`Long S, Cabral S, Horton C, Mehta J. Comparison of marrow and blood cell yields from the same
`donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation.
`Bone Marrow Transplant 2000; 25:501-505.
`
`
`92. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Mehta J. Long-term outcome of adult acute
`leukemia patients who are alive and well two years after allogeneic bone marrow transplantation from
`an HLA-identical sibling. Leuk Lymphoma 1999; 34:287-294.
`
`
`93. Singhal S, Powles R, Treleaven J, Kulkarni S, Horton C, Mehta J. Long-term outcome of adult acute
`leukemia patients who are alive and well 2 years after autologous blood or marrow transplantation.
`Bone Marrow Transplant 1999; 23:875-879.
`
`
`94. Singhal S, Mehta J, Desikan K, Siegel D, Singh J, Munshi N, Spoon D, Anaissie E, Ayers D, Barlogie
`B. Collection of peripheral blood stem cells after a preceding autograft: unfavorable effect of prior
`interferon-(cid:68) therapy. Bone Marrow Transplant 1999; 24:13-17.
`
`
`95. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, Munshi N, Singhal S, Mehta J,
`Tindle S, Nelson J, Bracy D, Mattox S, Tricot G. Comparable engraftment kinetics following
`peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without
`cyclophosphamide in multiple myeloma. J Clin Oncol 1998; 16:1547-1553.
`96. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, Tricot G, Munshi N, Fassas A,
`Singhal S, Mehta J, Anaissie E, Dhodapkar D, Naucke S, Cromer J, Sawyer J, Epstein J, Spoon D,
`Ayers D, Cheson B, Crowley J. Total therapy with tandem transplants for newly diagnosed multiple
`myeloma. Blood 1999; 93:55-65.
`
`
`97. Siegel DS, Desikan KR, Mehta J, Singhal S, Fassas A, Munshi N, Anaissie E, Naucke S, Ayers D,
`Spoon D, Vesole D, Tricot G, Barlogie B. Age is not a prognostic variable with autotransplants for
`multiple myeloma. Blood 1999; 93:51-54.
`
`
`
`Page 10 of 69
`
`Taro Pharmaceuticals, Ltd.
`Exhibit 1003
`
`

`

`98. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J, Siegel D, Shaughnessy J,
`Barlogie B. Identification of new nonrandom translocations in multiple myeloma with multicolor
`spectral karyotyping. Blood 1998; 92:4269-4278.
`
`
`99. Mehta J. Lipid preparations of amphotericin for the treatment of fungal infections. Br J Haematol 1999;
`105:845-847.
`
`
`100. Powles R, Mehta J, Kulkarni S, Treleaven J, Millar B, Marsden J, Shepherd V, Rowland A, Sirohi B,
`Tait D, Horton C, Long S, Singhal S. Allogeneic blood and bone-marrow stem-cell transplantation in
`haematological malignant diseases: a randomised trial. Lancet 2000; 355:1231-1237.
`
`
`101. Kulkarni S, Powles RL, Treleaven JG, Singhal S, Saso R, Horton C, Killick S, Tait D, Ramiah V,
`Mehta J. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma.
`Bone Marrow Transplant 1999; 23:675-680.
`
`
`102. Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, Saso R, Tait D, Treleaven JG,
`Powles RL. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-
`occlusive disease (VOD). Bone Marrow Transplant 1999; 23:803-807.
`
`
`103. Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V, Saso R, Horton C, Bhagwati N, Singhal
`S, Treleaven J. Complete remission rate and outcome after intensive treatment of 177 patients under
`75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system.
`Br J Haematol 1999; 107:656-666.
`
`
`104. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, Mehta J, Vesole D, Tricot G,
`Jagannath S, Anaissie E, Barlogie B, Munshi NC. High-dose therapy with autologous haematopoietic
`stem cell support for Waldenstrom’s macroglobulinaemia. Br J Haematol 1999; 105:993-996.
`
`
`105. Aslan T, Fassas ABT, Desikan R, Siegel D, Munshi NC, Mehta J, Singhal S, Barlogie B, Anaissie E.
`Patients with multiple myeloma may safely undergo autologous transplantation despite ongoing RSV
`infection and no ribavirin therapy. Bone Marrow Transplant 1999; 24:505-509.
`
`
`106. Singhal S, Powles R, Treleaven J, Kulkarni S, Sirohi B, Millar B, Shepherd V, Tait D, Horton C, Saso
`R, Rowland A, Long S, Mehta J. A low CD34+ cell dose results in higher mortality and poorer survival
`after blood or marrow stem cell transplantation from HLA-identical si